IP Library Patent Application 13964922
Patent Application
App. No. 13/964,922

MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/964,922
Abstract

Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure.

Claims (22)

1 . A composition comprising a benzodiazepine and a neurosteroid, wherein the composition comprises one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose.

2 . The composition of claim 1 , further comprising a NMDA receptor antagonist.

3 . The composition of claim 1 , wherein the composition is formulated for oral or transmucosal delivery or administration.

4 . The composition of claim 1 , wherein the composition is formulated for parenteral delivery.

5 . The composition of claim 4 , wherein the parenteral delivery or administration is via a route selected from the group consisting of inhalational, intrapulmonary, intramuscular, subcutaneous, transmucosal and intravenous.

6 . The composition of claim 1 , wherein the benzodiazepine is an agonist of the benzodiazepine recognition site on GABA A receptors and stimulates endogenous neurosteroid synthesis.

7 . The composition of claim 1 , wherein the benzodiazepine is selected from the group consisting of bretazenil, clonazepam, cloxazolam, clorazepate, diazepam, fludiazepam, flutoprazepam, lorazepam, midazolam, nimetazepam, nitrazepam, phenazepam, temazepam and clobazam.

8 . The composition of claim 1 , wherein the benzodiazepine is selected from the group consisting of midazolam, lorazepam and diazepam.

9 . The composition of claim 1 , wherein the neurosteroid is selected from the group consisting of allopregnanolone, allotetrahydrodeoxycorticosterone, ganaxolone, alphaxolone, alphadolone, hydroxydione, minaxolone, and Althesin.

10 . The composition of claim 1 , wherein the neurosteroid is allopregnanolone.

11 . The composition of claim 1 , wherein the composition comprises allopregnanolone and a benzodiazepine selected from the group consisting of midazolam, lorazepam and diazepam.

12 - 17 . (canceled)

18 . The composition of claim 2 , wherein the NMDA receptor antagonist is selected from the group consisting of dizocilpine (MK-801), meperidine, methadone, dextropropoxyphene, tramadol, ketobemidone, ketamine, dextromethorphan, phencyclidine, nitrous oxide (N 2 O), AP5 (R-2-amino-5-phosphonopentanoate), AP7 (2-amino-7-phosphonoheptanoic acid), CPPene (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic acid), selfotel, amantadine, dextrallorphan, dextromethorphan, dextrorphan, ethanol, eticyclidine, gacyclidine, ibogaine, magnesium, memantine, methoxetamine, rolicyclidine, tenocyclidine, methoxydine, tiletamine, xenon, neramexane, eliprodil, etoxadrol, dexoxadrol, WMS 2539, NEFA, remacemide, delucemine, 8A-PDHQ, aptiganel, HU-211, remacemide, rhynchophylline, 1 Aminocyclopropanecarboxylic acid (ACPC), 7-Chlorokynurenate, DCKA (5,7-dichlorokynurenic acid), kynurenic acid, and lacosamide.

19 . The composition of claim 2 , wherein the NMDA receptor antagonist is dizocilpine (MK-801).

20 . A method of preventing or terminating a seizure in a subject in need thereof, comprising administration to the subject of an effective amount of a composition of claim 1 .

21 . A method of accelerating the termination or abortion of an impending seizure in a subject in need thereof, comprising administration to the subject of an effective amount of a composition of claim 1 .

22 - 31 . (canceled)

32 . A method of preventing or terminating a seizure in a subject in need thereof, comprising administration to the subject of an effective amount of a benzodiazepine and a neurosteroid, wherein one or both of the benzodiazepine and the neurosteroid are administered in a subtherapeutic dose.

33 . A method of accelerating the termination or abortion of an impending seizure in a subject in need thereof, comprising administration to the subject of an effective amount of a benzodiazepine and a neurosteroid, wherein one or both of the benzodiazepine and the neurosteroid are administered in a subtherapeutic dose.

34 - 63 . (canceled)

64 . A kit comprising a benzodiazepine and a neurosteroid, wherein one or both of the benzodiazepine and the neurosteroid are provided in unit dosage forms comprising a subtherapeutic dose.

65 - 128 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: ROGAWSKI, MICHAEL A.; PESSAH, ISAAC N.; CAO, ZHENGYU; LEIN, PAMELA J.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 031234/0177 →